Highlights Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
39.15 ^HKD	+1.56%		+17.92%	-8.42%

Apr. 17	Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	CI
Apr. 02	Hutchmed endometrial cancer treatment application accepted for review	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	Apr. 02	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	Mar. 20	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	Mar. 06	CI
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	Mar. 05	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	Mar. 04	CI
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	Feb. 19	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	Feb. 07	CI
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	Feb. 06	MT
Innovent Bio's Weight Management Drug Trial Meets Primary and Secondary Endpoints	Jan. 09	MT
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints	Jan. 08	CI
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Enter Strategic Collaboration to Develop Sirna Drug for the Treatment of Hypertension	Dec. 26	CI
China?S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application of Taletrectinib	Dec. 18	CI
Innovent Biologics, Inc. Announces Publication of Mazdutide Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications	Dec. 17	CI
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study	Dec. 06	CI
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	Dec. 05	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351	Nov. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Highlights

Filters